PI3K/AKT/mTOR signaling-mediated neuropeptide VGF in the hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13

International Journal of Neuropsychopharmacology

Volumn 18, Issue 5, 2015, Pages 1-12

  Lu, Yang ^a   Wang, Chuang ^a   Xue, Zhancheng ^a   Li, Chenli ^a   Zhang, Junfang ^a   Zhao, Xin ^a   Liu, Aiming ^a   Wang, Qinwen ^a   Zhou, Wenhua ^a  

^a NINGBO UNIVERSITY   (China)

Author keywords

Depression; Glyx 13; Pi3k Akt Mtor Signaling; Vgf (Nonacryonimic)

Indexed keywords

AMPA RECEPTOR; ELONGATION FACTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; NEUROPEPTIDE; NEUROPEPTIDE VGF; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPASTINEL; UNCLASSIFIED DRUG; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTIDEPRESSANT AGENT; CHROMONE DERIVATIVE; ELONGATION FACTOR 2 KINASE; ENZYME INHIBITOR; GLYX-13 PEPTIDE; MORPHOLINE DERIVATIVE; MTOR PROTEIN, HUMAN; OLIGOPEPTIDE; TARGET OF RAPAMYCIN KINASE; VGF PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOWN REGULATION; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; MENTAL STRESS; METABOLISM; PHOSPHORYLATION; PSYCHOLOGY; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CHROMONES; DEPRESSION; ELONGATION FACTOR 2 KINASE; ENZYME INHIBITORS; HIPPOCAMPUS; MALE; MICE; MICE, INBRED ICR; MORPHOLINES; NEUROPEPTIDES; OLIGOPEPTIDES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL; SWIMMING; TOR SERINE-THREONINE KINASES;

EID: 84931263071     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyu110     Document Type: Article

References (44)

1. Abelaira HM, Reus GZ, Neotti MV, Quevedo J (2014) The role of mTOR in depression and antidepressant responses. Life Sci 101:10-14
2. Adell A, Castro E, Celada P, Bortolozzi A, Pazos A, Artigas F (2005) Strategies for producing faster acting antidepressants. Drug Discov Today 10:578-585
3. Adlard PA, Cotman CW (2004) Voluntary exercise protects against stress-induced decreases in brain-derived neurotrophic factor protein expression. Neuroscience 124:985-992
4. Alder J, Thakker-Varia S, Bangasser DA, Kuroiwa M, Plummer MR, Shors TJ, Black IB (2003) Brain-derived neurotrophic factorinduced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity. J Neurosci 23:10800-10808
5. Astle MV, Ooms LM, Cole AR, Binge LC, Dyson JM, Layton MJ, Petratos S, Sutherland C, Mitchell CA (2011) Identification of a proline-rich inositol polyphosphate 5-phosphatase (PIPP)collapsin response mediator protein 2 (CRMP2) complex that regulates neurite elongation. J Biol Chem 286:23407-23418
6. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91-95
7. Berton O, Nestler EJ (2006) New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7:137-151
8. Burgdorf J, Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK, Gross AL, Kroes RA, Moskal JR (2013) GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant- like effects without ketamine-like side effects. Neuropsychopharmacology 38:729-742
9. Castren E (2005) Is mood chemistry? Nat Rev Neurosci 6:241-246
10. Dranovsky A, Hen R (2006) Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry 59:1136-1143
11. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, Waterfield MD (2007) Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J. 404:15-21
12. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18:1926-1945
13. Hoeffer CA, Klann E (2010) mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 33:67-75
14. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627
15. Leibrock C, Ackermann TF, Hierlmeier M, Lang F, Borgwardt S, Lang UE (2013) Akt2 deficiency is associated with anxiety and depressive behavior in mice. Cell Physiol Biochem 32:766-777
16. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959-964
17. Li YF, Cheng YF, Huang Y, Conti M, Wilson SP, O'Donnell JM, Zhang HT. Phosphodiesterase-4D knock-out and RNA interferencemediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling (2011) J Neurosci 31:172-83
18. Lin P, Wang C, Xu B, Gao S, Guo J, Zhao X, Huang H, Zhang J, Chen X, Wang Q, Zhou W (2014) The VGF-derived peptide TLQP62 produces antidepressant-like effects in mice via the BDNF/ TrkB/CREB signaling pathway. Pharmacol Biochem Behav 120:140-148
19. Malberg JE, Monteggia LM (2008) VGF, a new player in antidepressant action? Sci Signal 1 pe19
20. Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW (2012) Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 26:189-204
21. Monteggia LM, Gideons E, Kavalali ET (2013) The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry 73:1199-1203
22. Moretti M, Budni J, Freitas AE, Rosa PB, Rodrigues AL (2014) Antidepressant- like effect of ascorbic acid is associated with the modulation of mammalian target of rapamycin pathway. J Psychiatr Res 48:16-24
23. Moskal JR, Kuo AG, Weiss C, Wood PL, O'Connor Hanson A, Kelso S, Harris RB, Disterhoft JF (2005) GLYX-13: a monoclonal antibody- derived peptide that acts as an N-methyl-D-Aspartate receptor modulator. Neuropharmacology 49:1077-1087
24. Moskal JR, Burch R, Burgdorf JS, Kroes RA, Stanton PK, Disterhoft JF, Leander JD (2014) GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs 23:243-254
25. Nasca C, Xenos D, Barone Y, Caruso A, Scaccianoce S, Matrisciano F, Battaglia G, Mathe AA, Pittaluga A, Lionetto L, Simmaco M, Nicoletti F (2013) L-Acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci U S A 110:4804-4809
26. Nedachi T, Kawai T, Matsuwaki T, Yamanouchi K, Nishihara M (2011) Progranulin enhances neural progenitor cell proliferation through glycogen synthase kinase 3? phosphorylation. Neuroscience 185:106-115
27. Numakawa T, Suzuki S, Kumamaru E, Adachi N, Richards M, Kunugi H (2010) BDNF function and intracellular signaling in neurons. Histol Histopathol 25:237-258
28. Numakawa T, Adachi N, Richards M, Chiba S, Kunugi H (2013) Brain-derived neurotrophic factor and glucocorticoids: reciprocal influence on the central nervous system. Neuroscience 239:157-172
29. Park SW, Lee JG, Seo MK, Lee CH, Cho HY, Lee BJ, Seol W, Kim YH (2014) Differential effects of antidepressant drugs on mTOR signalling in rat hippocampal neurons. Int J Neuropsychopharmacol 5:1-16
30. Sarkisyan G, Roberts AJ, Hedlund PB (2010) The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior. Behav Brain Res 209:99-108
31. Schosser A, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, Kasper S (2012) European Group for the Study of Resistant Depression (GSRD)-where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol 22:453-468
32. Thakker-Varia S, Behnke J, Doobin D, Dalal V, Thakkar K, Khadim F, Warner-Schmidt JL, Duman RS (2006) Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 16:239-249
33. Thakker-Varia S, Krol JJ, Nettleton J, Bilimoria PM, Bangasser DA, Shors TJ, Black IB, Alder J (2007) The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus. J Neurosci 27:12156-12167
34. Thakker-Varia S, Jean YY, Parikh P, Sizer CF, Jernstedt Ayer J, Parikh A, Hyde TM, Buyske S, Alder J (2010) The neuropeptide VGF is reduced in human bipolar postmortem brain and contributes to some of the behavioral and molecular effects of lithium. J Neurosci 30:9368-9380
35. Vahdati Hassani F, Naseri V, Razavi BM, Mehri S, Abnous K, Hosseinzadeh H (2014) Antidepressant effects of crocin and its effects on transcript and protein levels of CREB, BDNF, and VGF in rat hippocampus. Daru 22:16
36. Wang C, Yang XM, Zhuo YY, Zhou H, Lin HB, Cheng YF, Xu JP, Zhang HT (2012) The phosphodiesterase-4 inhibitor rolipram reverses A-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats. Int J Neuropsychopharmacol 15:749-66
37. Wilson E, Palmieri A, Antila H, Rantamaki T, Alder J (2014) VGF (TLQP-62)-induced neurogenesis targets early phase neural progenitor cells in the adult hippocampus and requires glutamate and BDNF signaling. Stem Cell Res 12:762-777
38. Wong ML, Licinio J (2004) From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 3:136-151
39. Yang C, Hu YM, Zhou ZQ, Zhang GF, Yang JJ (2013) Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test. Ups J Med Sci 118:3-8
40. Yang Q, Liao ZH, Xiao YX, Lin QS, Zhu YS, Li ST (2011) Hippocampal synaptic metaplasticity requires the activation of NR2Bcontaining NMDA receptors. Brain Res Bull 84:137-143
41. Zhang J, Guo J, Zhao X, Chen Z, Wang G, Liu A, Wang Q, Zhou W, Xu Y, Wang C (2013) Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-Amyloid levels and improves cognitive performance in APP/PS1 transgenic mice. Behav Brain Res 250:230-7
42. Zhang XL, Sullivan JA, Moskal JR, Stanton PK (2008) A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-DG synapses in hippocampus. Neuropharmacology 55:1238-1250
43. Zhou W, Wang N, Yang C, Li XM, Zhou ZQ, Yang JJ (2013) Ketamine- induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry pii:S0924-9338(13)00428-8
44. Zhou W, Dong L, Wang N, Shi JY, Yang JJ, Zuo ZY, Zhou ZQ (2014) Akt mediates GSK-3 phosphorylation in the rat prefrontal cortex during the process of ketamine exerting rapid antidepressant actions. Neuroimmunomodulation 21:183-188